Cite
HARVARD Citation
Gelmon, K. et al. (2020). Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer. Breast journal. 26 (3), pp. 368-375. [Online].